EN ISO 13485:2016 – Amendment 11 has been published!
The European standardisation bodies CEN and CENELEC published EN ISO 13485:2016+A11:2021 featuring new annexes ZA and ZB that link the requirements of the MDR (Regulation EU 2017/745) and the IVDR (Regulation EU 2017/746), respectively, to specific clauses of the standard.
Liliana Teles

Liliana Teles

Regulatory Affairs Manager

On the 9th of September, the European standardisation bodies CEN and CENELEC published the 2021 amendment, EN ISO 13485:2016+A11:2021 – ‘Medical devices – Quality management systems – Requirements for regulatory purposes’, featuring new annexes ZA and ZB that link the requirements of the Medical Device Regulation (MDR, EU 2017/745) and the In Vitro Diagnostics Regulation (IVDR, EU 2017/746), respectively, to specific clauses of the standard.

EN ISO 13485:2016+A11:2021 provides regulatory requirements for the manufacturer’s Quality Management System (QMS) that ensures consistent design, development, production, installation, and delivery of medical devices. Although ISO 13485:2016 is not mandatory for EU MDR/IVDR compliance, it is a commonly acknowledged standard to demonstrate the compliance to the MDR/IVDR requirement of having a QMS implemented.

What is new?

The new Annexes link clauses of the standard with requirements in the MDR and IVDR on:

– The general obligations of the manufacturer in MDR/IVDR Article 10 (Tables ZA1 for MDR and ZB1 for IVDR);

– The quality management system (QMS) requirements in MDR/IVDR Annex IX on conformity assessment based on a QMS and on assessment of technical documentation (Table ZA2 for MDR and ZB2 for IVDR); and

– The QMS requirements in MDR/IVDR Annex XI on conformity assessment based on product conformity verification (Table ZA3 for MDR and ZB3 for IVDR).

Annexes ZA and ZB publication now clarifies where compliance with the standard is not sufficient, or only partly sufficient, to meet EU regulatory requirements.

It is expected that the European Commission will add EN ISO 13485:2016+A11:2021 to the slowly growing list of standards harmonized under the MDR and the IVDR before the end of 2021, once reference to this standard is published in the Official Journal of the European Union, which would then allow medical device manufacturers to claim a presumption of conformity with identified clauses of the MDR/IVDR.

The current list of standards harmonized under the MDR/IVDR can be accessed here.

If you wish to know more information about amendment EN ISO 13485:2016+A11:2021 – ‘Medical devices – Quality management systems – Requirements for regulatory purposes’ feel free to contact us at info@criticalcatalyst.com.

further
reading

cosmetic products

The Responsible Person in the EU

Only cosmetic products for which a Responsible Person is designated in the European Union can be placed on the EU market. The Responsible Person must ensure full compliance with the European Cosmetic Regulation.

Read More »
cosmetic products

SCCS Preliminary Opinion on Genistein and Daidzein

The European Commission Scientific Committee on Consumer Safety (SCCS) has published its preliminary opinion on the use of Genistein and Daidzein in cosmetic products. The deadline for comments was set at 14 March 2022.

Read More »
cosmetic products

The Cosmetic Products Notification Portal (CPNP)

Only cosmetic products for which a legal or natural person is designated within the EU as a “Responsible Person” can be placed on the European Union (EU) market. Before placing a cosmetic product on the EU market, the RP must notify it in the Cosmetic Products Notification Portal (CPNP).

Read More »
cosmetic products

French Anti-Waste Law

The Loi relative à la lute contre le gaspillage et a l’économie circulaire (Anti-Waste for a circular economy) has come officially into force in France in 2020. Since the beginning of this year, some requirements of the law became mandatory, like the Triman logo. The law provides for a ban on all single-use plastics by 2040.

Read More »
cosmetic products

SCCS Preliminary Opinion on 4-MBC

In 2019, the European Commission set out two lists of ingredients suspected of having endocrine disrupting properties. As 4-MBC (UV-filter) was included in the higher priority group, the European Commission asked the SCCS to carry out a safety assessment on this ingredient. The preliminary version of the requested opinion was published.

Read More »
cosmetic products

SCCS Revision of the Opinion on Vitamin A

Vitamin A is not currently included in the Annexes of the European Cosmetics Regulation (Regulation (EC) No 1223/2009). The SCCS published the preliminary version of its revision of the scientific opinion on Vitamin A (retinol, retinyl palmitate and retinyl acetate). The deadline for comments was set at 7 February.

Read More »
medical devices

Person Responsible for Regulatory Compliance (PPRC) under MDR & IVDR

The EU Medical Device Regulation (EU MDR) and the EU In Vitro Diagnostic Device Regulation (EU IVDR) require all Manufacturers and Authorized Representatives to have a designated employee in their company who is responsible for regulatory compliance with the applicable MDR or IVDR requirements, the Person Responsible for Regulatory Compliance (PRRC).

Read More »